Table 4: Alternative therapeutic applications of allogeneic MSCs in liver cirrhosis patients.
Cell type | Dose | Route | Sample size (n) | Outcome | Reference |
UC-MSC | Three median doses/0.5 × 106 per kg body weight | Intravenous | 43 | Increased serum albumin, cholinesterase and platelet; Decreased MELD score, prothrombin time, total bilirubin and ALT |
[66] |
UC-MSC | Three median doses/0.5 × 106 per kg body weight | Intravenous | 7 | Decreased serum alkaline phosphatase and γ-glutamyltransferase | [25] |
UC-MSC | Three median doses/0.5 × 106 per kg body weight | Intravenous | 45 | Improvement in liver function | [25] |
UC-MSC | Single median dose/1.5 × 107 | Percutaneous | 51 | Improved QULI | [73] |